11 Presentations on Day 2 of Bionano Symposium 2026 Showcase Expanding Impact of Optical Genome Mapping Across Oncology and Cell & Gene Therapy

Core Insights - Bionano Genomics showcased the advancements of Optical Genome Mapping (OGM) in oncology and bioprocessing applications during Day 2 of Symposium 2026, emphasizing its potential as a new standard for detecting and characterizing structural variants in cancer [1][11] - The symposium attracted over 1,150 participants from 73 countries, marking it as the largest global event dedicated to OGM and Bionano solutions this year [2] - Presentations highlighted OGM's ability to reveal complex genomic events often missed by traditional methods, enhancing research and therapeutic innovation [3][11] Scientific Highlights - A study by Dr. Hippolyte Guerineau demonstrated OGM's high concordance with FISH in multiple myeloma samples while revealing additional structural complexities [4] - The FrOGG consortium, introduced by Dr. Agnes Daudignon, is standardizing OGM in onco-hematology across multiple countries and has initiated a national external quality control program [5] - Research by Dr. Ying Zou and Dr. Alejandro Berenguer Rubio showed that OGM detected significant structural variants in over 70% of soft tissue sarcoma samples, uncovering genomic rearrangements missed by conventional karyotyping [6] - Dr. Marc-Henri Stern presented an OGM-based assay for detecting homologous recombination deficiency in breast and ovarian cancers, achieving high predictive accuracy [7] - The 1000X Genome Project, co-presented by Dr. Adrian Dubuc and Dr. Phillip D. Michaels, aims to characterize the genomic architecture of plasma cell myeloma using ultra-deep OGM analysis [8] - OGM's application in engineered cell lines was demonstrated by Dr. Annelise Bennaceur-Griscelli and colleagues, highlighting its capability to detect variants introduced during development [9] Industry Implications - The presentations reinforced OGM's utility in advancing cancer research and bioprocessing, indicating a significant market opportunity beyond hematologic malignancies [11] - The ongoing discussions at the symposium focused on best practices for OGM implementation and future research directions, showcasing the collaborative efforts in the field [10][11]